Research Library

Peptide research, regulatory updates, and protocol intelligence.

Grounded in peer-reviewed literature and FDA prescribing data — the same sources that power the PeptidesGPT AI Coach.

May 12, 2026·5 min read

BPC-157, TB-500, and Epithalon: What's Actually Happening with FDA Reclassification in 2026

BPC-157 and TB-500 left the FDA's Category 2 restricted list on April 23, 2026. The FDA's PCAC meets July 23–24 to formally review 7 peptides for 503A approval. Here's what actually happened.

BPC-157TB-500EpithalonSemax

May 12, 2026·7 min read

Forzinity (SS-31) Receives FDA Accelerated Approval — Here's What It Means for the Peptide Field

SS-31 (Forzinity) received FDA accelerated approval in September 2025 for mitochondrial dysfunction — the first peptide of its class to cross from gray market to approved drug.

SS-31ElamipretideMOTS-cEpithalon